

# Future Perspectives in Bladder Tissue Engineering

Bradley C. Gill<sup>1,2,3</sup> · Margot S. Damaser<sup>1,2,3,4</sup> · Christopher J. Chermansky<sup>5</sup>

Published online: 16 September 2015  
© Springer Science+Business Media New York 2015

**Abstract** Substantial clinical need persists for improved autologous tissues to augment or replace the urinary bladder, and research has begun to address this using tissue engineering techniques. The implantation of both tissue scaffolds, which allow for native bladder tissue ingrowth, and autologous bladder grafts created from in-vitro cellularization of such scaffolds have been tested clinically; however, successful outcomes in both scenarios have been challenged by insufficient vascularity resulting from large graft sizes, which subsequently limits tissue ingrowth and leads to central graft ischemia. Consequently, recent research has focused on developing better methods to produce scaffolds with increased tissue ingrowth and vascularity. This review provides an update on bladder tissue engineering and outlines the challenges that remain to clinical implementation.

**Keywords** Urinary bladder · Regenerative urology · Tissue engineering · Stem cells · Autologous graft

## Introduction

There is a substantial clinical need for autologous tissue to augment or replace the urinary bladder, a complex organ with a multi-layered structure. The urothelium serves as an impenetrable barrier providing urine containment [1]. The lamina propria houses vasculature that provides essential oxygen and nutrients to the urothelium, while anchoring it to the bladder muscle [2]. The detrusor muscle facilitates low pressure urine storage and coordinated contractions to expel urine [3]. Individually, the layers serve specific roles; however, taken together, they are all necessary for the unique and essential functions of the bladder.

Tissue engineering and regenerative medicine have led to autologous bladder tissue creation. This occurs with either the implantation of scaffolds with subsequent ingrowth of surrounding bladder tissue layers, or via in-vitro generation of a bladder tissue graft using a cell-seeded scaffold [4]. Limited vascularity after implantation into the bladder remains a major challenge, thereby making viability of the regenerated tissue unreliable [5]. Furthermore, the ability of diseased bladder cells to successfully colonize scaffolds is often impaired, and the safety of their use in grafts may be limited by certain disease states, such as spina bifida or bladder cancer [6]. These factors highlight the potential for utilizing stem cells in creating autologous bladder tissues.

The field of regenerative urology is steadily growing, and with it, progress is being made in developing autologous bladder tissues. The need to replace or augment the bladder persists as the organ is removed for malignancy or fails secondary to inflammation, neurologic disease, injury, or aging. The

---

This article is part of the Topical Collection on *Reconstructed Bladder Function & Dysfunction*

---

✉ Christopher J. Chermansky  
chermanskycj2@upmc.edu

<sup>1</sup> Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA

<sup>2</sup> Lerner College of Medicine, Education Institute, Cleveland Clinic, Cleveland, OH, USA

<sup>3</sup> Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

<sup>4</sup> Advanced Platform Technology Center, Cleveland Veterans Affairs Medical Center, Cleveland, OH, USA

<sup>5</sup> Department of Urology, University of Pittsburgh Medical Center, 300 Halket St, Suite 4710, Pittsburgh, PA 15213, USA

ability of the bladder to regenerate from autologous cells will decidedly advance care for many urologic patients. The following review provides an update on bladder tissue engineering and the current challenges that limit clinical implementation.

### **Engineering Autologous Bladder Tissue Remains a Complex Challenge**

There remains a substantial need for partial or whole bladder replacement. Within the pediatric population, conditions such as bladder exstrophy, bladder outlet obstruction, and neurogenic bladder associated with spina bifida result in severe bladder dysfunction. In contrast, adult bladders are prone to anatomic and functional loss due to surgery, radiation, inflammation, repeated infection, denervation, or trauma. As the population ages, the prevalence of detrusor underactivity increases as well [7]. Bladder augmentation or replacement with bowel is often utilized when bladder capacity and compliance are poor; however, the use of bowel leads to metabolic, infectious, stone-related, and potential oncologic complications [8]. Therefore, there is a substantial clinical need for better autologous bladder tissue that augments or replaces the bladder without such unwanted consequences.

The urothelium is comprised of a multi-layered syncytium of epithelial cells that is impervious to urine. Urothelium displays surface properties which reduce the risk of infection, and it regenerates to cover areas denuded from various insults [9]. Its regenerative capability stems from a multi-layered structure, whereby the most mature cells lining the bladder are shed and replaced by younger cells in the deeper layers. This stratification also facilitates maintenance of the blood-urine barrier as the bladder stretches during filling [1]. Additionally, the urothelium contains cells which transduce bladder sensations, including irritation, distention, and pain [10]. Furthermore, various neurotrophins expressed in the urothelium are intricately involved in bladder function [11–13]. Overall, the viability of the urothelium depends upon the passive diffusion of oxygen and nutrients from the richly vascular lamina propria beneath it.

The bulk of the bladder is comprised of the lamina propria and detrusor muscle. The lamina propria anchors the urothelium to the detrusor and provides innervation [2]. The detrusor muscle has a rich intramural and superficial vascular network [3]. Both layers must be compliant as the bladder fills, in order to facilitate low pressure storage of urine. The detrusor muscle then generates an adequate and synchronous contraction to effectively expel urine from the bladder.

If the bladder undergoes abnormal development or is subject to a substantial insult that impairs its tissue quality, its regrowth and regeneration can be impaired. One example is the fibrotic, contracted bladder that can result from repeated

large transurethral bladder tumor resections, which likely results from cauterization of the underlying vascular supply. Similarly, pelvic radiation therapy, chronic inflammation, and recurrent urinary tract infections can cause fibrosis that decreases capacity and compliance, possibly resulting in a minimally functional end-stage bladder [14, 15]. In all these conditions, irritative voiding symptoms develop likely secondary to neural inflammation and altered neurotrophin levels [11]. Such neurologic effects probably interfere with coordinated bladder function, as well. Furthermore, one recent study showed impaired growth of bladder exstrophy smooth muscle and urothelial cells into a collagen scaffold. As such, the potential utilization of such scaffolds in diseased bladders remains uncertain [16]. This finding suggests a potential role for stem cells in re-cellularizing autologous bladder tissue in such disease states.

A variety of scaffold materials exists for bladder implantation or graft creation. These are comprised of both naturally derived and synthetic materials, either separately or in combination. In - vivo placement of scaffolds with surrounding tissue ingrowth and the in - vitro seeding of grafts have been studied for some time [17, 18]. The use of a scaffold implanted for the ingrowth of surrounding tissue requires a healthy bladder and is variably size-limited across species [19•]. The use of growth factors, such as vascular endothelial growth factor (VEGF) or basic fibroblast growth factor, compared to seeding scaffolds with stem cells or other supporting autologous cells, may address this limitation [4•]. Such factors may enable the growth of bladder tissue further into scaffold edges and result in implants with clinically useful sizes.

Similarly, the in-vitro initiation and development of cell layers onto grafts for later implantation may provide a viable solution. However, developing a robust multi-layered bladder graft is challenging because cell culture is often diffusion-limited to no more than 2 mm in depth [20]. Furthermore, one review summarized that vascular infiltration of tissues occurs at a rate of less than 1 mm daily and therefore can take up to 2 weeks to complete in a 3-mm thick tissue [21]. To date, the lack of vascularity upon implantation in such grafts has often resulted in decreased viability further from the graft-tissue interface [22•]. As such, the optimal solution to engineering a bladder graft requires further research.

### **The Current State of Autologous Bladder Tissue Engineering**

#### **Bladder Tissue Scaffolds**

Scaffolds for use in bladder tissue engineering are either derived from natural sources through decellularization and processing, or are created from synthetic materials using various fabrication techniques. Hybrid scaffolds that

incorporate elements of both have been developed with the aim of optimizing mechanical properties, degradation rates, intrinsic cytokine content, and cellular interactions [23]. One study utilized a porcine bladder acellular matrix and silk fibroin hybrid for scaffold implantation and observed successful cellularization [24]. Furthermore, the scaffold appeared to generate a multi-layered bladder wall consisting of urothelium, lamina propria, and detrusor muscle that resembled native control bladder; however, stone formation on the graft material and central graft perforation without vascular development also occurred [24]. These limitations highlight current challenges facing bladder tissue engineering research.

Altering the physical characteristics of a scaffold is one method of decreasing bladder stone formation and increasing cell adhesion. Two earlier studies highlight this by demonstrating how nanoscale surface characteristics reduce stone formation and improve urothelial cell coverage and smooth muscle ingrowth [25, 26]. More recently, a three-dimensional synthetic bi-material scaffold comprised of electrospun poly3-caprolactone and poly-L-lactic acid was created with specific nanometer - scale surface features that facilitated the growth of organized urothelial cells in - vitro [27]. Material engineering and nanotechnology fabrication techniques can serve as a means of incorporating important characteristics into scaffolds.

Scaffold content and structure are additional important considerations. To address insufficient vascularity, Jiang et al. utilized a 2 cm×3 cm scaffold of rabbit bladder acellular matrix and impregnated it with poly(lactid)glycolic acid nanoparticles to provide prolonged VEGF release [28•]. This resulted in increased microvessel density and reduced scaffold contraction and collagen content. Additionally, the scaffold was mechanically tested and demonstrated physical characteristics similar to the native bladder [28•]. This supports previous research in which incorporation of VEGF resulted in improved scaffold muscularity, angiogenesis, and innervation [29]. Similarly, integrating adipose-derived stem cells into a scaffold resulted in the development of mature urothelium, nerve, and bladder muscle [30]. This was in contrast to ingrowth of urothelium only in the scaffold alone group. These findings highlight the potential for utilizing molecular elements or cells to improve bladder tissue substitutes.

The mechanical characteristics and physiologic activity of the bladder tissue that forms on scaffolds is a crucial element of their design. Specifically, material selection for scaffold creation contributes to the mechanical properties of the graft prior to being resorbed. Also, the structure and organization of tissues that replace a scaffold determine the overall characteristics and functionality of the new bladder segment [31]. The finding that urinary diversion impairs the development of fetal bladders suggests a role for mechanical loading from filling and voiding in the organized formation of bladder tissues [32]. Similarly, when a scaffold was utilized for augmentation

cystoplasty in a canine model, animals that underwent prolonged catheter decompression of the bladder developed disorganized and fibrotic tissue at the scaffold site [33]. In contrast, limiting catheterization duration resulted in the growth of robust urothelium backed by increased vascularity, neuronal processes, and smooth muscle. This suggests that physiologic loading of bladder scaffolds is necessary for mature bladder tissue development.

### Bladder Tissue Grafts

In contrast to the use of bladder tissue scaffolds, the in-vitro creation of a bladder graft may provide an optimal solution for limited tissue development. This is particularly true in cases where diseased bladder cannot be used due to the risk of cancer or advanced bladder decompensation and fibrosis [16, 34, 35]. The ability to develop an in-vitro layer of urothelium onto grafts has been possible for some time [18]. Subsequent work has shown that urothelium can be generated from pluripotent stem cells, eliminating issues related to creating bladder tissue from a diseased source [36]. More recently, stratified grafts containing both urothelial and smooth muscle layers have been created and utilized clinically [22•, 37]. However, outcomes in these trials were limited due to implant contracture and central (distal) graft necrosis. Contraction and necrosis remain major challenges to autologous bladder graft success.

Insufficient vascularity in bladder grafts with subsequent implant contraction or perforation is a challenge similar to that witnessed in scaffolds with limited peripheral tissue ingrowth. Since cell culture techniques rely largely upon diffusion to maintain cell viability and support growth, the ability to form a sufficiently thick multi-layered tissue can be limited. Surgically, attempts have been made at improving graft perfusion after implantation by utilizing an omental overlay, but these interventions have been limited in their success by central graft degradation and perforation [22•]. This highlights the need to increase vascularity within autologous grafts in - vitro. However, the cell culture environment may not provide sufficient stimulus for functional vessel formation, which emphasizes improving graft vascularity as a priority area for research.

An excellent study utilizing partial cystectomy and bladder segment transplantation assessed the roles of graft and host vasculature and cellular regenerative capabilities. Osborn et al. demonstrated that native graft vessels remain intact centrally, while the proximal edges of a 5-mm bladder graft contained host vessel ingrowth and chimeric vessels [38•]. This suggests that inosculation is possible with a graft containing vasculature, and this facilitates graft survival. Furthermore, the results of this study showed that host stem cells do not contribute substantially to angiogenesis, but rather, they replace the donor urothelium [38•]. These findings further suggest that

the incorporation of vessels into bladder grafts developed *ex vivo* may contribute to their successful utilization.

Similar to scaffold implantation, the choice of material for *in-vitro* bladder graft creation is also an important factor. Materials should provide an ideal environment for the growth of urothelium, lamina propria, and smooth muscle [4•]. The substrate of the graft must also serve as a barrier to urine in order to protect the viability of the underlying lamina propria and smooth muscle layers until the urothelial barrier matures [5, 19•]. The material must display appropriate mechanical properties and degrade at the proper rate to optimize its integration into the bladder and minimize the risk of stone formation on the graft [39, 40]. As a bladder graft is developed in *in-vitro* and ideally comprised of three layers, expediting vascularity appears to be the most pressing issue to ensure tissue viability and minimize the risk of urine leakage.

Similar to scaffolds, material selection for graft creation contributes to mechanical properties of the tissue segment prior to being resorbed. Moreover, the structure of the newly grown tissue determines the overall physiologic characteristics of the implanted bladder segment [31]. Trials with human bladder graft placement and omental overlay have resulted in clinically insignificant changes in bladder pressure and volume, as well as a number of complications related to graft viability and omental flap placement [22•, 37]. Bladder decompression with continued catheter drainage was maintained postoperatively in these patients for 3 weeks, followed by bladder cycling (filling and emptying). With the resolution of graft viability issues, further research is needed to investigate the mechanical loading of the augmented bladder for optimization of the development of normal bladder architecture.

### Perspective on the Future of Autologous Bladder Tissue Engineering

The successful utilization of bladder scaffolds and bladder grafts is challenged by vascularity, which dictates the extent and rate of native bladder ingrowth and transplanted tissue survival. Most successful bladder scaffold experiments reported utilizing smaller implants since larger segments fail to facilitate viable multi-layered bladder tissue development [4•]. Similarly, urine leakage and graft contraction occur with implantation of large bladder grafts. Expediting vascular development within scaffolds using angiogenic growth factors or multipotent cell seeding could provide solutions for successful clinical implementation.

Since diffusion can support the ingrowth of bladder tissue at scaffold edges and sustain the viability of peripheral graft tissue, an alternative form of implantation could be considered to maximize contact of the graft with the native bladder edges. Otherwise, the use of non-omental vascularized structures,

such as demucosalized bowel and stomach segments, may warrant consideration due to their proven ability to sustain urothelial cells in *in-vivo* [41, 42]. Alternatively, a staged approach at augmentation that utilizes the incorporation of smaller viable graft segments may be explored. The field of autologous bladder tissue engineering remains a prime area for research with notable opportunities for innovation.

Aside from vascularity and viability, the challenge of creating structurally normal bladder tissue must be recognized. The ability to regenerate urothelium onto scaffolds and grafts has been proven for some time since urothelial cells are relatively easily replicated [18, 36]. Similarly, smooth muscle has been visualized in small scaffolds *in-vivo*, as well as certain grafts *in-vitro* [22•, 26]. A recent study demonstrated that graft preparation *in-vitro* using a type 1 collagen substrate seeded with bladder mesenchymal cells, when exposed to urine, produced urothelium with physiologic pseudostratification and cellular polarity [43]. Furthermore, the seeded bladder mesenchymal cells migrated to the urothelial layer, suggesting interaction between the two cell types. The authors of this study theorized that exposure to the molecular contents of urine provided an additional stimulus to promote more physiologic urothelial development. Further research in this area, and others such as formation of a robust lamina propria, is warranted.

Other components of bladder tissue critically important to optimize are its mechanical properties and physiologic functions. Normally, bladder volume increases in a highly compliant manner without a significant rise in pressure. A recent review suggested that bladder acellular matrix may be the optimal substrate for scaffolds and tissue grafts due to its retention of endogenous growth factors and its inherent biomechanical properties [19•]. Still, regardless of which autologous tissue substrate is utilized, to achieve optimal cellularization and adequate substrate degradation remains the biggest challenge. Furthermore, the exact role of how a mechanical stimulus remodels both bladder scaffolds and grafts remains unclear. Based upon observations made during both *in-utero* bladder development and in clinical trials of autologous bladder augmentation, insufficient mechanical stimulus from fill and empty cycles is associated with tissue fibrosis and poor compliance [22•, 32, 33, 37]. Investigation into the optimal approach to each of these factors is needed.

Even as *in-vivo* and *in-vitro* generation of urothelial and smooth muscle layers becomes routine, developing bladder tissue with a functional lamina propria may prove elusive. This remains an important consideration because of the vascularity and innervation that this tissue layer provides [2]. Based upon the current field of research, lamina propria creation seems to be less of a challenge with scaffold use because tissue ingrowth can result in a normally contracting and complete 3-layer bladder, especially when endogenous factors are utilized or exogenous ones are added; however, with larger scaffold sizes, this has not necessarily held true [4•, 19•, 28•,

29]. Since bi-layer materials have shown promise in graft creation, a tri-layer approach could be reasonable if cells incorporated in the center remain viable in a diffusion-limited cell culture environment [24, 27, 43]. Reliably obtaining a robust lamina propria remains a significant challenge.

## Considerations Moving Forward

With both stem cells and autologous bladder augments being tested in clinical trials, the field of regenerative urology is expanding. A substantial clinical need exists for autologous bladder tissue to either augment or replace the native bladder. It is essential that high-quality tissue is produced with normal structure, mechanical properties, and function. The ideal manner of achieving this has yet to be determined, but numerous options remain. The best substrate for scaffold or graft formation has yet to be identified, but a number of promising possibilities have been discovered. For individuals with a diseased bladder, stem cells provide an excellent option for graft seeding when autologous urothelium is unsafe or damaged. Additional optimization of autologous bladder tissue through improved vascularity is an area of active research, and the use of cytokines and stem cells will hopefully facilitate this. Lastly, clarifying the role of mechanical stimuli in improving scaffold or graft function is a key consideration that should not be underestimated.

Taken together, once autologous bladder tissue generation has been improved sufficiently, creation of an entirely autologous bladder represents the next visible frontier on the horizon. Each of the aforementioned challenges will be pertinent to this venture and potentially compounded in complexity once a three-dimensional structure is involved. Other new technologies and techniques will likely prove crucial as capabilities in autologous tissue development progress. Considering the use of grafts with vascular pedicles and tissue expanders in plastic and reconstructive surgery, could researchers grow a bladder elsewhere within the body and subsequently transplant it into its orthotopic position? The possibilities remain plentiful for the future of regenerative urology.

## Conclusions

Great progress has been made in bladder tissue engineering. However, clinical success with grafts remains inconsistent. Many challenges remain, and these are largely related to improving tissue vascularity and viability. Once these hurdles are passed, identifying the optimal means of bladder cycling for physiologic tissue organization is a remaining obstacle. The fields of materials engineering, stem cells, and

nanotechnology hold great potential for further advancement in bladder tissue engineering.

**Acknowledgments** Support provided in part from NIH R01 HD059859, NIH R21 HD078820, the Department of Veterans Affairs Rehabilitation Research and Development Service (VA Merit B7225R), and the Cleveland Clinic.

## Compliance with Ethics Guidelines

**Conflict of Interest** B.C. Gill declares that he has no conflicts of interest. According to M.S. Demaser, “Although I have grants from industry and a pending patent in the general field of testing regenerative agents for incontinence recovery, none is directly related to the material presented in this paper.” To quote C.J. Chermansky, “Although I am Co-investigator on 2 grants and a site PI on a multi-center industry trial, none is directly related to the material presented in this paper.”

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

## References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. Carattino MD, Prakasam HS, Ruiz WG, et al. Bladder filling and voiding affect umbrella cell tight junction organization and function. *Am J Physiol Ren Physiol*. 2013;305:F1158–68.
2. Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder? *Neurourol Urodyn*. 2014;33:9–16.
3. Shah AP, Mevcha A, Wilby D, et al. Continence and micturition: an anatomical basis. *Clin Anat*. 2014;27:1275–83.
4. Lin HK, Madhally SV, Palmer B, et al. Biomatrices for bladder reconstruction. *Adv Drug Deliv Rev*. 2015;82–83:47–63. **An in depth technical review and comparative analysis of bladder engineering techniques. Evaluates various scaffold and graft types, as well as modifications thereof, and their utilization for autologous bladder tissue engineering.**
5. Osborn SL, Kurzrock EA. Bioengineered bladder tissue—close but yet so far! *J Urol*. 2015;194:619–20.
6. Atala A. Regenerative bladder augmentation using autologous tissue—when will we get there? *J Urol*. 2014;191:1204–5.
7. van Koeveringe GA, Rademakers KL, Birder LA, et al. Detrusor underactivity: pathophysiological considerations, models and proposals for future research. ICI-RS 2013. *Neurourol Urodyn*. 2014;33:591–6.
8. Ng CK, Kauffman EC, Lee MM, et al. A comparison of postoperative complications in open versus robotic cystectomy. *Eur Urol*. 2010;57:274–81.
9. Khandelwal P, Abraham SN, Apodaca G. Cell biology and physiology of the uroepithelium. *Am J Physiol Ren Physiol*. 2009;297:F1477–501.
10. Birder L, Andersson KE. Urothelial signaling. *Physiol Rev*. 2013;93:653–80.
11. Ochodnick P, Cruz CD, Yoshimura N, Cruz F. Neurotrophins as regulators of urinary bladder function. *Nat Rev Urol*. 2012;9:628–37.

12. Girard BM, Malley SE, Vizzard MA. Neurotrophin/receptor expression in urinary bladder of mice with overexpression of NGF in urothelium. *Am J Physiol Ren Physiol*. 2011;300:F345–55.
13. Yuk SM, Shin JH, Song KH, et al. Expression of brain derived-neurotrophic factor and granulocyte-colony stimulating factor in the urothelium: relation with voiding function. *BMC Urol*. 2015;15:37. doi:10.1186/s12894-015-0036-3.
14. Deveaud CM, Macarak EJ, Kucich U, et al. Molecular analysis of collagens in bladder fibrosis. *J Urol*. 1998;160:1518–27.
15. Antonakopoulos GN, Hicks RM, Berry RJ. The subcellular basis of damage to the human urinary bladder induced by irradiation. *J Pathol*. 1984;143:103–16.
16. Roelofs LA, Kortmann BB, Oosterwijk E, et al. Tissue engineering of diseased bladder using a collagen scaffold in a bladder exstrophy model. *BJU Int*. 2014;114:447–57.
17. Koiso K, Komai T, Nijima T. Experimental urinary bladder reconstruction using a synthetic poly(alpha-amino acids) membrane. *Artif Organs*. 1983;7:232–7.
18. Atala A, Freeman MR, Vacanti JP, et al. Implantation in vivo and retrieval of artificial structures consisting of rabbit and human urothelium and human bladder muscle. *J Urol*. 1993;150:608–12.
19. Song L, Murphy SV, Yang B, et al. Bladder acellular matrix and its application in bladder augmentation. *Tissue Eng B Rev*. 2014;20:163–72. **A review of bladder acellular matrix and its use in augmentation cystoplasty. Reviews the various modifications that have been made to the substrate in differing studies. Highlights that this may be the scaffold of choice moving forward due to its endogenous growth factors and physiologic structure.**
20. Griffith CK, Miller C, Sainson RC, et al. Diffusion limits of an in vitro thick prevascularized tissue. *Tissue Eng*. 2005;11:257–66.
21. Nomi M, Atala A, Coppi PD, Soker S. Principals of neovascularization for tissue engineering. *Mol Asp Med*. 2002;23:463–83.
22. Joseph DB, Borer JG, De Filippo RE, et al. Autologous cell seeded biodegradable scaffold for augmentation cystoplasty: phase II study in children and adolescents with spina bifida. *J Urol*. 2014;191:1389–95. **A multicenter clinical study of autologous graft bladder augmentation in children with omental flap overlay. The results of this trial show there is room for improvement in graft viability as well as function.**
23. Pokrywczynska M, Gubanska I, Drewa G, Drewa T. Application of bladder acellular matrix in urinary bladder regeneration: the state of the art and future directions. *Biomed Res Int*. 2015;2015:613439.
24. Zhao Y, He Y, Guo JH, et al. Time-dependent bladder tissue regeneration using bilayer bladder acellular matrix graft-silk fibroin scaffolds in a rat bladder augmentation model. *Acta Biomater*. 2015;23:91–102.
25. Chun YW, Khang D, Haberstroh KM, Webster TJ. The role of polymer nanosurface roughness and submicron pores in improving bladder urothelial cell density and inhibiting calcium oxalate stone formation. *Nanotechnology*. 2009;20:085104. doi:10.1088/0957-4484/20/8/085104.
26. Thapa A, Webster TJ, Haberstroh KM. Polymers with nano-dimensional surface features enhance bladder smooth muscle cell adhesion. *J Biomed Mater Res A*. 2003;67:1374–83.
27. Naji M, Rasouli J, Shakhssalim N, et al. Supportive features of a new hybrid scaffold for urothelium engineering. *Arch Med Sci*. 2015;11:438–45.
28. Jiang X, Xiong Q, Xu G, et al. VEGF-loaded nanoparticle-modified BAMAs enhance angiogenesis and inhibit graft shrinkage in tissue-engineered bladder. *Ann Biomed Eng*. 2015;43(10):2577–86. **A study showing bladder acellular matrix scaffolds enhanced with vascular endothelial growth factor nanoparticles have better vascularity. Reduced contraction of the implanted acellular scaffolds was also observed.**
29. Youssif M, Shiina H, Urakami S, et al. Effect of vascular endothelial growth factor on regeneration of bladder acellular matrix graft: histologic and functional evaluation. *Urology*. 2005;66:201–7.
30. Zhu WD, Xu YM, Feng C, et al. Bladder reconstruction with adipose-derived stem cell-seeded bladder acellular matrix grafts improve morphology composition. *World J Urol*. 2010;28:493–8.
31. Zimmern PE, Lin VK, McConnell JD. Smooth-muscle physiology. *Urol Clin N Am*. 1996;23:211–9.
32. Wei W, Howard PS, Kogan B, Macarak EJ. Urinary diversion results in marked decreases in proliferation and apoptosis in fetal bladder. *J Urol*. 2012;188:1306–12.
33. Boruch AV, Nieponice A, Qureshi IR, et al. Constructive remodeling of biologic scaffolds is dependent on early exposure to physiologic bladder filling in a canine partial cystectomy model. *J Surg Res*. 2010;161:217–25.
34. Burmeister DM, AbouShwareb T, Bergman CR, et al. Age-related alterations in regeneration of the urinary bladder after subtotal cystectomy. *Am J Pathol*. 2013;183:1585–95.
35. Caione P, Boldrini R, Salerno A, Nappo SG. Bladder augmentation using acellular collagen biomatrix: a pilot experience in exstrophic patients. *Pediatr Surg Int*. 2012;28:421–8.
36. Osborn SL, Kurzrock EA. Production of urothelium from pluripotent stem cells for regenerative applications. *Curr Urol Rep*. 2015;16:466. doi:10.1007/s11934-014-0466-6.
37. Atala A, Bauer SB, Soker S, et al. Tissue-engineered autologous bladders for patients needing cystoplasty. *Lancet*. 2006;367:1241–6.
38. Osborn SL, So M, Hambro S, et al. Inosculation of blood vessels allows early perfusion and vitality of bladder grafts-implications for bioengineered bladder wall. *Tissue Eng A*. 2015;21:1906–15. **A study utilizing autologous bladder patch transplants to study vascularization of tissue grafts. Results showed that host vascularization occurs minimally at graft edges with chimeric vessel formation to take advantage of the established donor tissue circulation.**
39. Sharma AK. Is a functional urinary bladder attainable through current regenerative medicine strategies? *Cent European J Urol*. 2013;66:207–8.
40. Horst M, Madduri S, Gobet R, et al. Engineering functional bladder tissues. *J Tissue Eng Regen Med*. 2013;7:515–22.
41. Abdel Hay S, Soliman SM, Debeky ME. Urothelial ingrowth over demucosalized gastrocystoplasty: an experimental study. *BJU Int*. 2002;90:945–9.
42. Hidas G, Lee HJ, Bahoric A, et al. Aerosol transfer of bladder urothelial and smooth muscle cells onto demucosalized colonic segments for bladder augmentation: in vivo, long term, and functional pilot study. *J Pediatr Urol*. 2015. doi:10.1016/j.jpuro.2015.02.020
43. Bouhout S, Goulet F, Bolduc S. A novel and faster method to obtain a differentiated 3-dimensional tissue engineered bladder. *J Urol*. 2015;194:834–41.